<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство и гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0300-9092</issn><issn publication-format="electronic">2412-5679</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">248904</article-id><article-id pub-id-type="doi">10.18565/aig.2020.5.122-30</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">INVESTIGATION OF THE EFFICACY OF INDOLE-3-CARBINOL ON A RAT MODEL OF ENDOMETRIOSIS (EXPERIMENTAL STUDY)</article-title><trans-title-group xml:lang="ru"><trans-title>ИЗУЧЕНИЕ ЭФФЕКТИВНОСТИ ИНДОЛ-3-КАРБИНОЛА НА МОДЕЛИ ЭНДОМЕТРИОЗА У КРЫС (ЭКСПЕРИМЕНТАЛЬНОЕ ИССЛЕДОВАНИЕ)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>KISELEV</surname><given-names>Vsevolod I.</given-names></name><name xml:lang="ru"><surname>КИСЕЛЕВ</surname><given-names>Всеволод Иванович</given-names></name></name-alternatives><bio xml:lang="en"><p>Doctor of Biological Sciences, Professor, Corresponding Member of RAS Professor, Deputy Director if the Institute of Oncogynecology and Mammology</p></bio><bio xml:lang="ru"><p>д.б.н., профессор, член-корреспондент РАН, заместитель директора Института онкогинекологии и маммологии</p></bio><email>vkisl0@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>ASHRAFYAN</surname><given-names>Levon A.</given-names></name><name xml:lang="ru"><surname>АШРАФЯН</surname><given-names>Левон Андреевич</given-names></name></name-alternatives><bio xml:lang="en"><p>DM, Professor, Academician of the Russian Academy of Sciences, Director оf the Institute of Oncogynecology and Mammology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН, заслуженный врач РФ, заместитель директора, директор Института онкогинекологии и маммологии</p></bio><email>levaa2004@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>PRONIN</surname><given-names>Stanislav M.</given-names></name><name xml:lang="ru"><surname>ПРОНИН</surname><given-names>Станислав Михайлович</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, Oncologist, Senior scientific researcher at the Institute of Oncogynecology and Mammology</p></bio><bio xml:lang="ru"><p>к.м.н., врач-онколог, старший научный сотрудник Института онкогинекологии и маммологии</p></bio><email>s_pronin@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>GERFANOVA</surname><given-names>Evgeniya V.</given-names></name><name xml:lang="ru"><surname>ГЕРФАНОВА</surname><given-names>Евгения Викторовна</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, Oncologist at the Institute of Oncogynecology and Mammology</p></bio><bio xml:lang="ru"><p>врач-онколог Института онкогинекологии и маммологии</p></bio><email>e_gerfanova@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>KUZNETSOV</surname><given-names>Igor N.</given-names></name><name xml:lang="ru"><surname>КУЗНЕЦОВ</surname><given-names>Игорь Николаевич</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD, Deputy Director if the Institute of Oncogynecology and Mammology</p></bio><bio xml:lang="ru"><p>к.б.н., заместитель директора Института онкогинекологии и маммологии</p></bio><email>i_kuznetsov@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>DRUKH</surname><given-names>Vadim M.</given-names></name><name xml:lang="ru"><surname>ДРУХ</surname><given-names>Вадим Михайлович</given-names></name></name-alternatives><bio xml:lang="en"><p>DM, General Director</p></bio><bio xml:lang="ru"><p>д.м.н., генеральный директор</p></bio><email>info@mbpharma.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>UDUT</surname><given-names>Vladimir V.</given-names></name><name xml:lang="ru"><surname>УДУТ</surname><given-names>Владимир Васильевич</given-names></name></name-alternatives><bio xml:lang="en"><p>DM, Professor, Corresponding Member of RAS, Deputy Director of Scientific and Medical Work, Head of the Laboratory of Physiology, Molecular and Clinical Pharmacology Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, член-корреспондент РАН, заместитель директора по научной и лечебной работе, заведующий лабораторией физиологии, молекулярной и клинической фармакологии НИИФиРМ им. Е.Д. Гольдберга</p></bio><email>udutv@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>CHURIN</surname><given-names>Alexey A.</given-names></name><name xml:lang="ru"><surname>ЧУРИН</surname><given-names>Алексей Александрович</given-names></name></name-alternatives><bio xml:lang="en"><p>DM, Head of the Department of Drug Toxicology, Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg</p></bio><bio xml:lang="ru"><p>д.м.н., заведующий отделом лекарственной токсикологии НИИФиРМ им. Е.Д. Гольдберга</p></bio><email>churin_aa@pharmso.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>PCHELINTSEVA</surname><given-names>Olga I.</given-names></name><name xml:lang="ru"><surname>ПЧЕЛИНЦЕВА</surname><given-names>Ольга Игоревна</given-names></name></name-alternatives><bio xml:lang="en"><p>MSc, Clinical trial manager</p></bio><bio xml:lang="ru"><p>менеджер по клиническим исследованиям</p></bio><email>pchelintseva87@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">AO «MiraxBioPharma»</institution></aff><aff><institution xml:lang="ru">АО «МираксБиоФарма»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Tomsk National Research Medical Center</institution></aff><aff><institution xml:lang="ru">Томский НИМЦ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2020</year></pub-date><issue>5</issue><issue-title xml:lang="en">NO5 (2020)</issue-title><issue-title xml:lang="ru">№5 (2020)</issue-title><fpage>122</fpage><lpage>130</lpage><history><date date-type="received" iso-8601-date="2023-02-18"><day>18</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО «Бионика Медиа»</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0300-9092/article/view/248904">https://journals.eco-vector.com/0300-9092/article/view/248904</self-uri><abstract xml:lang="en"><p>Objective. To investigate the pharmacological activity of a drug with the active substance indole-3-carbinol on a rat model of endometriosis. Materials and methods. An experiment was carried out on on pubertal female rats (n = 60). According to pathology modeling and therapy, the animals were divided into groups. Group 1 consisted of falsely operated animals receiving starch solution. Group 2 included falsely operated ones given indole-3-carbinol at a dose of111 mg/kg. In Groups 3 to 5, endometriosis was modelled by autologous transplantation of endometrial tissue into the peritoneal cavity. Group 3 animals received 1% starch solution; Groups 4 and 5 had the active substance at doses of 37 and 111 mg/kg, respectively. Reactions to pain were studied in the animals and implants were also histologically assessed at 30 and 60 days. Results. The untreated animals with induced pathology showed a more pronounced pain response than falsely operated animals. Histological estimation revealed that endometrial hyperplasia tended to reduce in the groups of females that had received the active substance compared with that in the control groups. Conclusion. The investigation showed that indole-3-carbinol administered to the animals effectively decreased the size of an endometrioid focus and the degree of endometrioid heterotopies, thereby indicating the therapeutic effect on endometriosis-induced pain syndrome.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Изучение фармакологической активности лекарственного средства с действующим веществом индолкарбинол на модели эндометриоза у крыс. Материалы и методы. Эксперимент проводился на половозрелых самках крыс (60 животных). Животные были разделены на группы в соответствии с моделированием патологии и терапией. Группа 1 - ложнооперированные животные, получавшие раствор крахмала, группа 2 - ложнооперированные животные, получавшие индолкарбинол в дозировке 111 мг/кг. В группах 3-5 проводилось моделирование эндометриоза путем аутологичной трансплантации эндометриальной ткани в брюшную полость. Животные 3-й группы получали 1% раствор крахмала, 4-й группы - активный препарат в дозировке 37 мг/кг, животные 5-й группы - активный препарат в дозировке 111 мг/кг. Изучали болевую реакцию животных, а также на 30-й и 60-й день проводили гистологическую оценку имплантатов. Результаты. У животных с индуцированной патологией, не получавших лечения, наблюдалась более выраженная болевая реакция по сравнению с ложнооперированными животными. По результатам гистологической оценки выявлена тенденция к снижению степени гиперплазии эндометрия в группах самок, получавших активный препарат, по сравнению с контрольными группами. Выводы. Исследование показало, что индолкарбинол при введении животным эффективно снижал размер эндометриоидного очага и выраженность эндометриоидных гетеротопий, за счет чего было показано терапевтическое действие в отношении болевого синдрома, вызванного развитием эндометриоза.</p></trans-abstract><kwd-group xml:lang="en"><kwd>endometriosis</kwd><kwd>preclinical trials</kwd><kwd>indole-3-carbinol</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эндометриоз</kwd><kwd>доклинические исследования</kwd><kwd>индол-3-карбинол</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Маржевская В.В., Присяжная Т.С., Жамойдик В.И., Берлев И.В., Малек А.В. Молекулярно-генетические основы эндометриоза: диагностический потенциал наследуемых и экспрессируемых факторов. Журнал акушерства и женских болезней. 2018; 67(3): 64-73.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Адамян Л.В., ред. Клинические рекомендации по ведению больных. Эндометриоз: диагностика, лечение и реабилитация. М.; 2013.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zhou W.J., Yang H.L., Shao J., Mei J., Chang K.K., Zhu R., Li M.Q. Antiinflammatory cytokines in endometriosis. Cell. Mol. Life Sci. 2019; 76(11): 2111-32. https://dx.doi.org/10.1007/s00018-019-03056-x.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bulun S.E., Monsivais D., Kakinuma T., Furukawa Y., Bernardi L., Pavone M.E., Dyson M. Molecular biology of endometriosis: from aromatase to genomic abnormalities. Semin. Reprod. Med. 2015; 33(3): 220-4. https://dx.doi. org/10.1055/s-0035-1554053.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Donnez J. Introduction: From pathogenesis to therapy, deep endometriosis remains a source of controversy. Fertil. Steril. 2017; 108(6): 869-71. https:// dx.doi.org/10.1016/j.fertnstert.2017.10.015.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Киселев В.И., Пальцев М.А. Регуляция активности генов и новые лекарственные средства. Вестник Российской академии наук. 2016; 86(6): 512-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Clemenza S., Sorbi F., Noci I., Capezzuoli T., Turrini I., Carriero C. et al. From pathogenesis to clinical practice: Emerging medical treatments for endometriosis. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 92-101. https://dx.doi. org/10.1016/j.bpobgyn.2018.01.021.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Aggarwal B.B., Ichikawa H. Molecular targets and anticancer potential of indole- 3-carbinol and its derivatives. Cell Cycle. 2005; 4(9): 1201-15. https://dx.doi. org/10.4161/cc.4.9.1993.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Fujioka N., Fritz V., Upadhyaya P., Kassie F., Hecht S.S. Research on cruciferous vegetables, indole-3-carbinol, and cancer prevention: A tribute to Lee W. Wattenberg. Mol. Nutr. Food Res. 2016; 60(6): 1228-38. https://dx.doi. org/10.1002/mnfr.201500889.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cover C.M., Hsieh S.J., Cram E.J., Hong C., Riby J.E., Bjeldanes L.F., Firestone G.L. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res. 1999; 59(6): 1244-51.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ampofo E., Schmitt B.M., Menger M.D., Laschke M.W. Targeting the Microcirculation by indole-3-carbinol and its main derivate 3,3,’-diindolylmethane: effects on angiogenesis, thrombosis and inflammation. Mini Rev. Med. Chem. 2018; 18(11): 962-8. https://dx.doi.org/10.2174/13895 57518666180313100144.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rahman K.M., Aranha O., Sarkar F.H. Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr. Cancer. 2003; 45(1): 101-12.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Feitelson M.A., Arzumanyan A., Kulathinal R.J., Blain S.W., Holcombe R.F., Mahajna J. et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin. Cancer Biol. 2015; 35(Suppl.): S25-54. https://dx.doi.org/10.1016/j.semcancer.2015.02.006.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Fuentes F., Paredes-Gonzalez X., Kong A.N. Dietary glucosinolates sulforaphane, phenethyl isothiocyanate, indole-3-carbinol/3,3’-diindolylmethane: antioxidative stress/inflammation, Nrf2, epigenetics/epigenomics and in vivo cancer chemopreventive efficacy. Curr. Pharmacol. Rep. 2015; 1(3): 179-96. https:// dx.doi.org/10.1007/s40495-015-0017-y.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ahmad A., Sakr W.A., Rahman K.W. Mechanisms and therapeutic implications of cell death induction by indole compounds. Cancers (Basel). 2011; 3(3): 2955-74. https://dx.doi.org/10.3390/cancers3032955.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Maruthanila V.L., Poornima J., Mirunalini S. Attenuation of carcinogenesis and the mechanism underlying by the influence of indole-3-carbinol and its metabolite 3,3’-diindolylmethane: a therapeutic marvel. Adv. Pharmacol. Sci. 2014;2014:832161. https://dx.doi.org/10.1155/2014/832161.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang S.Q., Cheng L.S., Liu Y., Wang J.Y., Jiang W. Indole-3-carbinol (I3C) and its major derivatives: their pharmacokinetics and important roles in hepatic protection. Curr. Drug Metab. 2016; 17(4): 401-9. https://dx.doi.org/10.2174/ 1389200217666151210125105.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Riby J.E., Firestone G.L., Bjeldanes L.F. 3,3’-diindolylmethane reduces levels of HIF-1alpha and HIF-1 activity in hypoxic cultured human cancer cells. Biochem. Pharmacol. 2008; 75(9): 1858-67. https://dx.doi.org/10.1016/j. bcp.2008.01.017.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Augoulea A., Alexandrou A., Creatsa M., Vrachnis N., Lambrinoudaki I. Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress. Arch. Gynecol. Obstet. 2012; 286(1): 99-103. https://dx.doi.org/10.1007/ s00404-012-2357-8.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Киселев В.И., Сметник В.П., Сутурина Л.В., Селиванов С.П., Рудакова Е.Б., Рахматуллина И.Р., Андреева Е.Н., Фадеева Н.И., Хасанов Р.Ш., Кулагина Н.В., Рожкова Н.И., Артымук Н.В., Гависова А.А., Муйжнек Е.Л., Кузнецов И.Н., Друх В.М. Индолкарбинол (Индинол Форто) - метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013; 7: 56-62.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Anesthesia and analgesia in laboratory animals at UCSF. The Regents of the University of California. Электронный ресурс: Available at: http://www.iacuc. ucsf.edu/Proc/awRbtFrm.asp Accessed 01.2019.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Keenan J.A., Williams-Boyce P.K., Massey P.J., Chen T.T., Caudle M.R., Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil. Steril. 1999; 72(1): 135-41. https://dx.doi.org/10.1016/s0015-0282(99)00157-0.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Tosti C., Biscione A., Morgante G., Bifulco G., Luisi S., Petraglia F. Hormonal therapy for endometriosis: from molecular research to bedside. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 209: 61-6. https://dx.doi.org/10.1016/j. ejogrb.2016.05.032.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Simmen R.C., Kelley A.S. Reversal of fortune: estrogen receptor-ß in endometriosis. J. Mol. Endocrinol. 2016; 57(2): F23-7. https://dx.doi. org/10.1530/JME-16-0080.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician gynecologists. Int. J. Gynaecol. Obstet. 2000; 71(2): 183-96. https://dx.doi.org/10.1016/s0020-7292(00)80034-x.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Shertzer H.G., Senf A.P. The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metabol. Drug Interact. 2000; 17(1-4): 159-88. https://dx.doi.org/ 10.1515/dmdi.2000.17.1-4.159.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Rogan E.G. The natural chemopreventive compound indole-3-carbinol: state of the science. In Vivo. 2006; 20(2): 221-8.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Тихончук Е.Ю., Асатурова А.В., Адамян Л.В. Частота выявления и структура патологических изменений эндометрия у женщин репродуктивного возраста с генитальным эндометриозом. Акушерство и гинекология. 2016; 12: 87-95.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ищенко А.И., Кудрина Е.А. Эндометриоз: диагностика и лечение. М.: ГЭОТАР-МЕД; 2002. 104 с.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ahmad A., Biersack B., Li Y., Kong D., Bao B., Schobert R. et al. Targeted regulation of PI3K/Akt/mTOR/NF-kB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med. Chem. 2013; 13(7): 1002-13. https://dx.doi. org/10.2174/18715206113139990078.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Wang X., He H., Lu Y., Ren W., Teng K.Y., Chiang C.L. et al. Indole-3-carbinol inhibits tumorigenicity of hepatocellular carcinoma cells via suppression of microRNA-21 and upregulation of phosphatase and tensin homolog. Biochim. Biophys. Acta. 2015; 1853(1): 244-53. https://dx.doi.org/10.1016/j. bbamcr.2014.10.017.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Marconett C.N., Singhal A.K., Sundar S.N., Firestone G.L. Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells. Mol. Cell. Endocrinol. 2012; 363(1-2): 74-84. https://dx.doi. org/10.1016/j.mce.2012.07.008.</mixed-citation></ref></ref-list></back></article>
